EGFR and K-ras mutations as determinants of gefitinib sensitivity in non-small-cell lung cancer (NSCLC).

被引：0
|
作者：
Han, SW
Jeong, S
Choi, IS
Kim, DN
Chung, DH
Im, SA
Kim, TY
Heo, DS
Bang, YJ
Kim, NK
机构：
[1] Seoul Natl Univ, Coll Med, Seoul, South Korea
[2] ISU ABXIS Inc, Seoul, South Korea
[3] Seoul Municipal Boramae Hosp, Seoul, South Korea
[4] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：639S / 639S
页数：1
相关论文
共 50 条
  • [31] Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer
    Califano, Raffaele
    Landi, Lorenza
    Cappuzzo, Federico
    DRUGS, 2012, 72 : 28 - 36
  • [32] Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer
    Raffaele Califano
    Lorenza Landi
    Federico Cappuzzo
    Drugs, 2012, 72 : 28 - 36
  • [33] Prognostic implications of K-ras mutations in operable non-small cell lung cancer
    Lee, J
    Kim, C
    Ryoo, B
    Yang, S
    Choe, D
    Koh, J
    LUNG CANCER, 2005, 49 : S134 - S134
  • [34] Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
    Maemondo, Makoto
    Inoue, Akira
    Kobayashi, Kunihiko
    Sugawara, Shunichi
    Oizumi, Satoshi
    Isobe, Hiroshi
    Gemma, Akihiko
    Harada, Masao
    Yoshizawa, Hirohisa
    Kinoshita, Ichiro
    Fujita, Yuka
    Okinaga, Shoji
    Hirano, Haruto
    Yoshimori, Kozo
    Harada, Toshiyuki
    Ogura, Takashi
    Ando, Masahiro
    Miyazawa, Hitoshi
    Tanaka, Tomoaki
    Saijo, Yasuo
    Hagiwara, Koichi
    Morita, Satoshi
    Nukiwa, Toshihiro
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25): : 2380 - 2388
  • [35] Non-small-cell lung cancer (NSCLC) tumors from gefitinib-responsive patients (pts) harbor EGFR kinase domain mutations
    Rosell, Rafael
    Ichinose, Yukito
    Taron, Miquel
    Sarries, Carme
    Queralt, Cristina
    Ono, Mayumi
    Manegold, Christian
    Mok, Tony
    Miguel Sanchez, Jose
    Massuti, Bartomeu
    ANNALS OF ONCOLOGY, 2004, 15 : 166 - 166
  • [36] Modification of mutant K-ras gene expression in non-small cell lung cancer (NSCLC)
    Roth, JA
    HUMAN GENE THERAPY, 1996, 7 (07) : 875 - 889
  • [37] K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer
    Y Fukuyama
    T Mitsudomi
    K Sugio
    T Ishida
    K Akazawa
    K Sugimachi
    British Journal of Cancer, 1997, 75 : 1125 - 1130
  • [38] EGFR AND K-RAS MUTATIONS IN JAPANESE PATIENTS WITH RESECTED NSCLC
    Shiina, Takayuki
    Saito, Gaku
    Ushiyama, Toshiki
    Toishi, Masayuki
    Hamanaka, Kazutoshi
    Kurai, Makoto
    Takasuna, Keiichiro
    Kondo, Ryoichi
    Yoshida, Kazuo
    Amano, Jun
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1492 - S1493
  • [39] K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer
    Fukuyama, Y
    Mitsudomi, T
    Sugio, K
    Ishida, T
    Akazawa, K
    Sugimachi, K
    BRITISH JOURNAL OF CANCER, 1997, 75 (08) : 1125 - 1130
  • [40] Infra-tumor heterogeneity in non-small-cell lung cancer (NSCLC) carrying EGFR mutations
    Rachiglio, Anna Maria
    lambiase, Matilde
    Fenizia, Francesca
    Morabito, Alessandro
    Rocco, Gaetano
    Galetta, Domenico
    Ludovini, Vienna
    Vincenzi, Bruno
    Barletta, Emiddio
    Botti, Gerardo
    Normanno, Nicola
    CANCER RESEARCH, 2016, 76
12345